SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/11/23 Intercept Pharmaceuticals, Inc. SC 14D9 1:1M Intercept Pharmaceuticals, Inc. Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: SC 14D9 Tender-Offer Solicitation/Recommendation Statement HTML 962K
tm2327968-1_sc14d9 - none - 9.8125412s |
Name
|
| |
Position
|
|
Jerome Durso | | | President and Chief Executive Officer | |
Andrew Saik | | | Chief Financial Officer | |
Michelle Berrey | | |
President of Research & Development and Chief Medical Officer
|
|
Linda Richardson | | | Chief Commercial Officer | |
Jared Freedberg | | | General Counsel | |
David Ford | | | Chief Human Resources Officer | |
Rocco Venezia | | | Chief Accounting Officer | |
Name of Officer or Director
|
| |
Number of Shares
Beneficially Owned |
| |
Cash Consideration
Payable in Respect of Shares ($) |
| ||||||
Paolo Fundarò
|
| | | | 35,794 | | | | | | 680,086 | | |
| | | | 51,815 | | | | | | 984,485 | | | |
Srinivas Akkaraju(1)
|
| | | | 678,575 | | | | | | 12,892,925 | | |
Luca Benatti
|
| | | | 25,487 | | | | | | 484,253 | | |
Daniel Bradbury(2)
|
| | | | 31,360 | | | | | | 595,840 | | |
Keith Gottesdiener
|
| | | | 24,719 | | | | | | 469,661 | | |
Nancy Miller-Rich
|
| | | | 22,304 | | | | | | 423,776 | | |
Mark Pruzanski
|
| | | | 618,894 | | | | | | 11,758,986 | | |
Dagmar Rosa-Bjorkeson
|
| | | | 14,766 | | | | | | 280,554 | | |
Gino Santini
|
| | | | 23,645 | | | | | | 449,255 | | |
Glenn Sblendorio
|
| | | | 23,447 | | | | | | 445,493 | | |
Andrew Saik
|
| | | | 23,021 | | | | | | 437,399 | | |
Michelle Berrey
|
| | | | 28,349 | | | | | | 538,631 | | |
Linda Richardson
|
| | | | 16,706 | | | | | | 317,414 | | |
Name of Officer or Director
|
| |
Number of Shares
Beneficially Owned |
| |
Cash Consideration
Payable in Respect of Shares ($) |
| ||||||
Jared Freedberg
|
| | | | 20,685 | | | | | | 393,015 | | |
David Ford
|
| | | | 15,038 | | | | | | 285,722 | | |
Rocco Venezia
|
| | | | 10,782 | | | | | | 204,858 | | |
Name of Officer or Director
|
| |
Number
of Shares Subject to Vested Company Options (#) |
| |
Weighted
Average Exercise Price per Share (Vested Company Options) ($) |
| |
Cash
Consideration for Vested Company Options ($) |
| |
Number
of Shares Subject to Unvested Company Options (#) |
| |
Weighted
Average Exercise Price per Share (Unvested Company Options) ($) |
| |
Cash
Consideration for Unvested Company Options ($) |
| |
Total Cash
Consideration for Company Options ($) |
| |||||||||||||||||||||
Paolo Fundarò
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
| | | | 26,643 | | | | | | 14.44 | | | | | | 121,492 | | | | | | 116,957 | | | | | | 17.24 | | | | | | 205,832 | | | | | | 327,324 | | | |
Srinivas Akkaraju
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Luca Benatti
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Daniel Bradbury
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Keith Gottesdiener
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Nancy Miller-Rich
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Mark Pruzanski
|
| | | | 0 | | | | | | — | | | | | | 0 | | | | | | 0 | | | | | | — | | | | | | 0 | | | | | | 0 | | |
Dagmar Rosa-Bjorkeson
|
| | | | 24,603 | | | | | | 16.94 | | | | | | 50,563 | | | | | | 18,453 | | | | | | 11.70 | | | | | | 134,677 | | | | | | 185,240 | | |
Name of Officer or Director
|
| |
Number
of Shares Subject to Vested Company Options (#) |
| |
Weighted
Average Exercise Price per Share (Vested Company Options) ($) |
| |
Cash
Consideration for Vested Company Options ($) |
| |
Number
of Shares Subject to Unvested Company Options (#) |
| |
Weighted
Average Exercise Price per Share (Unvested Company Options) ($) |
| |
Cash
Consideration for Unvested Company Options ($) |
| |
Total Cash
Consideration for Company Options ($) |
| |||||||||||||||||||||
Gino Santini
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Glenn Sblendorio
|
| | | | 24,879 | | | | | | 16.95 | | | | | | 51,093 | | | | | | 12,547 | | | | | | 9.17 | | | | | | 123,337 | | | | | | 174,430 | | |
Andrew Saik
|
| | | | 7,700 | | | | | | 14.44 | | | | | | 35,112 | | | | | | 33,900 | | | | | | 17.24 | | | | | | 59,544 | | | | | | 94,656 | | |
Michelle Berrey
|
| | | | 7,700 | | | | | | 14.44 | | | | | | 35,112 | | | | | | 33,900 | | | | | | 17.24 | | | | | | 59,544 | | | | | | 94,656 | | |
Linda Richardson
|
| | | | 7,700 | | | | | | 14.44 | | | | | | 35,112 | | | | | | 29,900 | | | | | | 17.09 | | | | | | 57,144 | | | | | | 92,256 | | |
Jared Freedberg
|
| | | | 7,700 | | | | | | 14.44 | | | | | | 35,112 | | | | | | 29,900 | | | | | | 17.09 | | | | | | 57,144 | | | | | | 92,256 | | |
David Ford
|
| | | | 4,943 | | | | | | 14.44 | | | | | | 22,540 | | | | | | 22,357 | | | | | | 17.27 | | | | | | 38,588 | | | | | | 61,128 | | |
Rocco Venezia
|
| | | | 2,668 | | | | | | 14.44 | | | | | | 12,166 | | | | | | 19,432 | | | | | | 17.70 | | | | | | 25,250 | | | | | | 37,416 | | |
Name of Officer
|
| |
Number of Shares
Subject to Company PSUs |
| |
Cash Consideration
Payable in Respect of Shares Subject to Company PSUs ($) |
| ||||||
| | | | 497,750 | | | | | | 9,457,250 | | | |
Andrew Saik
|
| | | | 37,500 | | | | | | 712,500 | | |
Michelle Berrey
|
| | | | 37,500 | | | | | | 712,500 | | |
Linda Richardson
|
| | | | 42,950 | | | | | | 816,050 | | |
Jared Freedberg
|
| | | | 33,750 | | | | | | 641,250 | | |
David Ford
|
| | | | 33,800 | | | | | | 642,200 | | |
Rocco Venezia
|
| | | | 20,100 | | | | | | 381,900 | | |
Name of Officer or Director
|
| |
Number of Shares
Subject to Company RSUs |
| |
Cash Consideration
Payable in Respect of Shares Subject to Company RSUs ($) |
| ||||||
Paolo Fundarò
|
| | | | 8,111 | | | | | | 154,109 | | |
| | | | 102,825 | | | | | | 1,953,675 | | | |
Srinivas Akkaraju
|
| | | | 8,111 | | | | | | 154,109 | | |
Luca Benatti
|
| | | | 8,111 | | | | | | 154,109 | | |
Daniel Bradbury
|
| | | | 8,111 | | | | | | 154,109 | | |
Keith Gottesdiener
|
| | | | 8,111 | | | | | | 154,109 | | |
Nancy Miller-Rich
|
| | | | 8,111 | | | | | | 154,109 | | |
Mark Pruzanski
|
| | | | 0 | | | | | | 0 | | |
Dagmar Rosa-Bjorkeson
|
| | | | 11,625 | | | | | | 220,875 | | |
Gino Santini
|
| | | | 8,111 | | | | | | 154,109 | | |
Glenn Sblendorio
|
| | | | 8,111 | | | | | | 154,109 | | |
Andrew Saik
|
| | | | 45,244 | | | | | | 859,636 | | |
Michelle Berrey
|
| | | | 51,790 | | | | | | 984,010 | | |
Linda Richardson
|
| | | | 26,585 | | | | | | 505,115 | | |
Jared Freedberg
|
| | | | 36,529 | | | | | | 694,051 | | |
David Ford
|
| | | | 21,400 | | | | | | 406,600 | | |
Rocco Venezia
|
| | | | 14,669 | | | | | | 278,711 | | |
Name of Officer
|
| |
Estimated Payment
for Long-Term Cash Incentives ($) |
| |||
| | | | 2,250,000 | | | |
Andrew Saik
|
| | | | 1,225,000 | | |
Michelle Berrey
|
| | | | 2,225,000 | | |
Linda Richardson
|
| | | | 1,025,000 | | |
Jared Freedberg
|
| | | | 1,025,000 | | |
David Ford
|
| | | | 562,500 | | |
Rocco Venezia
|
| | | | 562,500 | | |
Name of Officer
|
| |
2023 Annual Bonus at
Assumed 125% Performance Level |
| |||
| | | | 658,743 | | | |
Andrew Saik
|
| | | | 320,450 | | |
Michelle Berrey
|
| | | | 404,625 | | |
Linda Richardson
|
| | | | 323,700 | | |
Jared Freedberg
|
| | | | 311,350 | | |
David Ford
|
| | | | 292,500 | | |
Rocco Venezia
|
| | | | 252,743 | | |
Name
|
| |
Cash
Severance ($) |
| |
Value of Benefit
Continuation ($) |
| ||||||
David Ford
|
| | | | 468,000 | | | | | | 39,361 | | |
Rocco Venezia
|
| | | | 404,390 | | | | | | 24,960 | | |
| | |
2023
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
|
Total Net Sales
|
| |
$330
|
| |
$360
|
| |
$365
|
| |
$385
|
| |
$381
|
| |
$388
|
| |
$435
|
| |
$500
|
| |
$562
|
|
Total Operating Expenses
|
| |
($355)
|
| |
($226)
|
| |
($202)
|
| |
($210)
|
| |
($221)
|
| |
($229)
|
| |
($242)
|
| |
($240)
|
| |
($224)
|
|
EBITDA
|
| |
($25)
|
| |
$134
|
| |
$163
|
| |
$175
|
| |
$160
|
| |
$159
|
| |
$193
|
| |
$260
|
| |
$338
|
|
| | |
2023
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
|
Total Revenue
|
| |
$333
|
| |
$355
|
| |
$363
|
| |
$423
|
| |
$386
|
| |
$388
|
| |
$385
|
| |
$415
|
| |
$434
|
| |
$332
|
|
Total Gross Profit
|
| |
$331
|
| |
$353
|
| |
$360
|
| |
$420
|
| |
$383
|
| |
$384
|
| |
$377
|
| |
$399
|
| |
$413
|
| |
$312
|
|
R&D Expense
|
| |
($138)
|
| |
($97)
|
| |
($78)
|
| |
($75)
|
| |
($77)
|
| |
($56)
|
| |
($57)
|
| |
($52)
|
| |
($35)
|
| |
($17)
|
|
SG&A Expense
|
| |
($241)
|
| |
($146)
|
| |
($142)
|
| |
($152)
|
| |
($161)
|
| |
($164)
|
| |
($158)
|
| |
($148)
|
| |
($144)
|
| |
($97)
|
|
Operating Income
|
| |
($48)
|
| |
$109
|
| |
$141
|
| |
$193
|
| |
$145
|
| |
$164
|
| |
$161
|
| |
$200
|
| |
$234
|
| |
$197
|
|
NOPAT
|
| |
($48)
|
| |
$86
|
| |
$111
|
| |
$152
|
| |
$115
|
| |
$130
|
| |
$127
|
| |
$158
|
| |
$185
|
| |
$155
|
|
Unlevered Free Cash Flow
|
| |
$9(1)
|
| |
$72
|
| |
$111
|
| |
$144
|
| |
$120
|
| |
$129
|
| |
$123
|
| |
$147
|
| |
$177
|
| |
$168
|
|
| | |
2033
|
| |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
|
Total Revenue
|
| |
$336
|
| |
$343
|
| |
$351
|
| |
$359
|
| |
$368
|
| |
$377
|
| |
$386
|
| |
$85
|
| |
$69
|
| |
$62
|
|
Total Gross Profit
|
| |
$315
|
| |
$321
|
| |
$328
|
| |
$336
|
| |
$344
|
| |
$352
|
| |
$361
|
| |
$80
|
| |
$65
|
| |
$59
|
|
R&D Expense
|
| |
($9)
|
| |
($4)
|
| |
($2)
|
| |
($1)
|
| |
($1)
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
|
SG&A Expense
|
| |
($99)
|
| |
($101)
|
| |
($103)
|
| |
($106)
|
| |
($109)
|
| |
($111)
|
| |
($114)
|
| |
($25)
|
| |
($20)
|
| |
($18)
|
|
Operating Income
|
| |
$207
|
| |
$216
|
| |
$223
|
| |
$229
|
| |
$235
|
| |
$241
|
| |
$247
|
| |
$55
|
| |
$45
|
| |
$41
|
|
NOPAT
|
| |
$164
|
| |
$171
|
| |
$176
|
| |
$181
|
| |
$185
|
| |
$190
|
| |
$195
|
| |
$44
|
| |
$36
|
| |
$32
|
|
Unlevered Free Cash Flow
|
| |
$163
|
| |
$169
|
| |
$174
|
| |
$179
|
| |
$184
|
| |
$188
|
| |
$193
|
| |
$100
|
| |
$39
|
| |
$33
|
|
| | |
2023
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
|
Total Revenue
|
| |
$333
|
| |
$352
|
| |
$352
|
| |
$401
|
| |
$350
|
| |
$333
|
| |
$312
|
| |
$315
|
| |
$309
|
| |
$246
|
|
Total Gross Profit
|
| |
$331
|
| |
$349
|
| |
$350
|
| |
$399
|
| |
$347
|
| |
$331
|
| |
$306
|
| |
$303
|
| |
$293
|
| |
$230
|
|
R&D Expense
|
| |
($138)
|
| |
($97)
|
| |
($78)
|
| |
($75)
|
| |
($77)
|
| |
($56)
|
| |
($57)
|
| |
($52)
|
| |
($35)
|
| |
($17)
|
|
SG&A Expense
|
| |
($241)
|
| |
($146)
|
| |
($142)
|
| |
($152)
|
| |
($153)
|
| |
($152)
|
| |
($142)
|
| |
($130)
|
| |
($124)
|
| |
($85)
|
|
Operating Income
|
| |
($48)
|
| |
$106
|
| |
$130
|
| |
$172
|
| |
$117
|
| |
$123
|
| |
$106
|
| |
$121
|
| |
$134
|
| |
$128
|
|
NOPAT
|
| |
($48)
|
| |
$84
|
| |
$103
|
| |
$136
|
| |
$93
|
| |
$97
|
| |
$84
|
| |
$95
|
| |
$106
|
| |
$101
|
|
Unlevered Free Cash Flow
|
| |
$9(1)
|
| |
$69
|
| |
$104
|
| |
$128
|
| |
$100
|
| |
$99
|
| |
$82
|
| |
$90
|
| |
$103
|
| |
$109
|
|
| | |
2033
|
| |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
|
Total Revenue
|
| |
$249
|
| |
$255
|
| |
$261
|
| |
$267
|
| |
$274
|
| |
$281
|
| |
$288
|
| |
$63
|
| |
$51
|
| |
$46
|
|
Total Gross Profit
|
| |
$233
|
| |
$239
|
| |
$244
|
| |
$250
|
| |
$256
|
| |
$263
|
| |
$270
|
| |
$59
|
| |
$48
|
| |
$43
|
|
R&D Expense
|
| |
($9)
|
| |
($4)
|
| |
($2)
|
| |
($1)
|
| |
($1)
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
|
SG&A Expense
|
| |
($86)
|
| |
($88)
|
| |
($90)
|
| |
($93)
|
| |
($95)
|
| |
($98)
|
| |
($100)
|
| |
($22)
|
| |
($17)
|
| |
($16)
|
|
Operating Income
|
| |
$139
|
| |
$146
|
| |
$152
|
| |
$156
|
| |
$161
|
| |
$165
|
| |
$169
|
| |
$37
|
| |
$30
|
| |
$27
|
|
NOPAT
|
| |
$109
|
| |
$115
|
| |
$120
|
| |
$123
|
| |
$127
|
| |
$130
|
| |
$134
|
| |
$30
|
| |
$24
|
| |
$22
|
|
Unlevered Free Cash Flow
|
| |
$108
|
| |
$114
|
| |
$118
|
| |
$122
|
| |
$125
|
| |
$128
|
| |
$132
|
| |
$71
|
| |
$26
|
| |
$22
|
|
| | |
2023
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
|
Total Revenue
|
| |
$333
|
| |
$348
|
| |
$342
|
| |
$384
|
| |
$326
|
| |
$304
|
| |
$272
|
| |
$261
|
| |
$248
|
| |
$194
|
|
Total Gross Profit
|
| |
$331
|
| |
$346
|
| |
$339
|
| |
$381
|
| |
$324
|
| |
$302
|
| |
$266
|
| |
$252
|
| |
$236
|
| |
$182
|
|
R&D Expense
|
| |
($138)
|
| |
($97)
|
| |
($78)
|
| |
($75)
|
| |
($77)
|
| |
($48)
|
| |
($49)
|
| |
($44)
|
| |
($30)
|
| |
($15)
|
|
SG&A Expense
|
| |
($241)
|
| |
($146)
|
| |
($142)
|
| |
($152)
|
| |
($147)
|
| |
($145)
|
| |
($133)
|
| |
($121)
|
| |
($114)
|
| |
($71)
|
|
Operating Income
|
| |
($48)
|
| |
$102
|
| |
$120
|
| |
$154
|
| |
$100
|
| |
$109
|
| |
$84
|
| |
$87
|
| |
$92
|
| |
$96
|
|
NOPAT
|
| |
($48)
|
| |
$81
|
| |
$95
|
| |
$122
|
| |
$79
|
| |
$86
|
| |
$66
|
| |
$68
|
| |
$73
|
| |
$76
|
|
Unlevered Free Cash Flow
|
| |
$9(1)
|
| |
$67
|
| |
$96
|
| |
$116
|
| |
$87
|
| |
$88
|
| |
$65
|
| |
$63
|
| |
$69
|
| |
$82
|
|
| | |
2033
|
| |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
|
Total Revenue
|
| |
$196
|
| |
$200
|
| |
$205
|
| |
$210
|
| |
$215
|
| |
$221
|
| |
$226
|
| |
$50
|
| |
$40
|
| |
$36
|
|
Total Gross Profit
|
| |
$184
|
| |
$188
|
| |
$192
|
| |
$196
|
| |
$201
|
| |
$206
|
| |
$211
|
| |
$47
|
| |
$38
|
| |
$34
|
|
R&D Expense
|
| |
($7)
|
| |
($4)
|
| |
($2)
|
| |
($1)
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
|
SG&A Expense
|
| |
($72)
|
| |
($74)
|
| |
($75)
|
| |
($77)
|
| |
($79)
|
| |
($81)
|
| |
($84)
|
| |
($18)
|
| |
($15)
|
| |
($13)
|
|
Operating Income
|
| |
$104
|
| |
$110
|
| |
$115
|
| |
$118
|
| |
$121
|
| |
$124
|
| |
$128
|
| |
$29
|
| |
$23
|
| |
$21
|
|
NOPAT
|
| |
$82
|
| |
$87
|
| |
$90
|
| |
$93
|
| |
$96
|
| |
$98
|
| |
$101
|
| |
$23
|
| |
$18
|
| |
$17
|
|
Unlevered Free Cash Flow
|
| |
$81
|
| |
$85
|
| |
$89
|
| |
$91
|
| |
$94
|
| |
$96
|
| |
$99
|
| |
$61
|
| |
$20
|
| |
$17
|
|
| | |
2023
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
|
Total Revenue
|
| |
$333
|
| |
$348
|
| |
$342
|
| |
$384
|
| |
$326
|
| |
$313
|
| |
$259
|
| |
$219
|
| |
$167
|
| |
$33
|
|
Total Gross Profit
|
| |
$331
|
| |
$346
|
| |
$339
|
| |
$381
|
| |
$324
|
| |
$311
|
| |
$257
|
| |
$217
|
| |
$166
|
| |
$33
|
|
R&D Expense
|
| |
($138)
|
| |
($97)
|
| |
($78)
|
| |
($75)
|
| |
($77)
|
| |
($10)
|
| |
($10)
|
| |
($10)
|
| |
($10)
|
| |
$0
|
|
SG&A Expense
|
| |
($241)
|
| |
($146)
|
| |
($142)
|
| |
($152)
|
| |
($147)
|
| |
($147)
|
| |
($130)
|
| |
($113)
|
| |
($101)
|
| |
($20)
|
|
Operating Income
|
| |
($48)
|
| |
$102
|
| |
$120
|
| |
$154
|
| |
$100
|
| |
$154
|
| |
$117
|
| |
$94
|
| |
$55
|
| |
$13
|
|
NOPAT
|
| |
($48)
|
| |
$81
|
| |
$95
|
| |
$122
|
| |
$79
|
| |
$122
|
| |
$92
|
| |
$74
|
| |
$44
|
| |
$10
|
|
Unlevered Free Cash Flow
|
| |
$9(1)
|
| |
$67
|
| |
$96
|
| |
$116
|
| |
$87
|
| |
$123
|
| |
$98
|
| |
$78
|
| |
$49
|
| |
$27
|
|
| | |
2033
|
| |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
|
Total Revenue
|
| |
$27
|
| |
$24
|
| |
$22
|
| |
$20
|
| |
$18
|
| |
$16
|
| |
$14
|
| |
$13
|
| |
$12
|
| |
$10
|
|
Total Gross Profit
|
| |
$27
|
| |
$24
|
| |
$22
|
| |
$19
|
| |
$17
|
| |
$16
|
| |
$14
|
| |
$13
|
| |
$11
|
| |
$10
|
|
R&D Expense
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
| |
$0
|
|
SG&A Expense
|
| |
($15)
|
| |
($12)
|
| |
($10)
|
| |
($9)
|
| |
($8)
|
| |
($7)
|
| |
($6)
|
| |
($6)
|
| |
($5)
|
| |
($5)
|
|
Operating Income
|
| |
$12
|
| |
$12
|
| |
$12
|
| |
$11
|
| |
$9
|
| |
$9
|
| |
$8
|
| |
$7
|
| |
$6
|
| |
$6
|
|
NOPAT
|
| |
$9
|
| |
$9
|
| |
$9
|
| |
$8
|
| |
$8
|
| |
$7
|
| |
$6
|
| |
$5
|
| |
$5
|
| |
$4
|
|
Unlevered Free Cash Flow
|
| |
$10
|
| |
$9
|
| |
$9
|
| |
$8
|
| |
$8
|
| |
$7
|
| |
$6
|
| |
$6
|
| |
$5
|
| |
$4
|
|
| | |
2023
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
|
Total Revenue
|
| |
$333
|
| |
$353
|
| |
$348
|
| |
$388
|
| |
$333
|
| |
$317
|
| |
$316
|
| |
$331
|
| |
$339
|
| |
$232
|
|
Total Gross Profit
|
| |
$331
|
| |
$350
|
| |
$346
|
| |
$386
|
| |
$330
|
| |
$314
|
| |
$309
|
| |
$320
|
| |
$325
|
| |
$218
|
|
R&D Expense
|
| |
($138)
|
| |
($97)
|
| |
($78)
|
| |
($75)
|
| |
($74)
|
| |
($62)
|
| |
($60)
|
| |
($55)
|
| |
($38)
|
| |
($17)
|
|
SG&A Expense
|
| |
($241)
|
| |
($146)
|
| |
($142)
|
| |
($152)
|
| |
($161)
|
| |
($165)
|
| |
($167)
|
| |
($158)
|
| |
($153)
|
| |
($102)
|
|
Operating Income
|
| |
($48)
|
| |
$107
|
| |
$126
|
| |
$159
|
| |
$95
|
| |
$88
|
| |
$83
|
| |
$107
|
| |
$134
|
| |
$98
|
|
NOPAT
|
| |
($48)
|
| |
$84
|
| |
$100
|
| |
$125
|
| |
$75
|
| |
$69
|
| |
$65
|
| |
$85
|
| |
$106
|
| |
$78
|
|
| | |
2033
|
| |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
|
Total Revenue
|
| |
$233
|
| |
$237
|
| |
$241
|
| |
$246
|
| |
$251
|
| |
$257
|
| |
$263
|
| |
$61
|
| |
$50
|
| |
$45
|
|
Total Gross Profit
|
| |
$218
|
| |
$222
|
| |
$226
|
| |
$230
|
| |
$235
|
| |
$240
|
| |
$246
|
| |
$58
|
| |
$47
|
| |
$42
|
|
R&D Expense
|
| |
($9)
|
| |
($4)
|
| |
($2)
|
| |
($1)
|
| |
($1)
|
| |
($0)
|
| |
($0)
|
| |
($0)
|
| |
($0)
|
| |
($0)
|
|
SG&A Expense
|
| |
($103)
|
| |
($104)
|
| |
($106)
|
| |
($108)
|
| |
($110)
|
| |
($113)
|
| |
($115)
|
| |
($27)
|
| |
($22)
|
| |
($20)
|
|
Operating Income
|
| |
$107
|
| |
$113
|
| |
$118
|
| |
$121
|
| |
$124
|
| |
$127
|
| |
$130
|
| |
$30
|
| |
$25
|
| |
$22
|
|
NOPAT
|
| |
$85
|
| |
$90
|
| |
$93
|
| |
$96
|
| |
$98
|
| |
$101
|
| |
$103
|
| |
$24
|
| |
$20
|
| |
$18
|
|
| | |
4Q’23
|
| |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
|
NOPAT
|
| |
$5
|
| |
$84
|
| |
$100
|
| |
$125
|
| |
$75
|
| |
$69
|
| |
$65
|
| |
$85
|
| |
$106
|
| |
$78
|
|
Less: Capital Expenditures
|
| |
($1)
|
| |
($2)
|
| |
($2)
|
| |
($2)
|
| |
($2)
|
| |
($2)
|
| |
($2)
|
| |
($2)
|
| |
($2)
|
| |
($1)
|
|
Less: Change in NWC
|
| |
$4
|
| |
($14)
|
| |
$1
|
| |
($6)
|
| |
$8
|
| |
$2
|
| |
$0
|
| |
($2)
|
| |
($1)
|
| |
$14
|
|
Plus: Depreciation
|
| |
$1
|
| |
$2
|
| |
$2
|
| |
$2
|
| |
$2
|
| |
$2
|
| |
$2
|
| |
$2
|
| |
$2
|
| |
$1
|
|
Unlevered Free Cash Flow
|
| |
$9
|
| |
$70
|
| |
$101
|
| |
$119
|
| |
$83
|
| |
$71
|
| |
$65
|
| |
$83
|
| |
$105
|
| |
$92
|
|
| | |
2033
|
| |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
|
NOPAT
|
| |
$85
|
| |
$90
|
| |
$93
|
| |
$96
|
| |
$98
|
| |
$101
|
| |
$103
|
| |
$24
|
| |
$20
|
| |
$18
|
|
Less: Capital Expenditures
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($0)
|
| |
($0)
|
| |
($0)
|
|
Less: Change in NWC
|
| |
($0)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
($1)
|
| |
$26
|
| |
$1
|
| |
$1
|
|
Plus: Depreciation
|
| |
$1
|
| |
$1
|
| |
$1
|
| |
$1
|
| |
$1
|
| |
$1
|
| |
$1
|
| |
$0
|
| |
$0
|
| |
$0
|
|
Unlevered Free Cash Flow
|
| |
$85
|
| |
$89
|
| |
$92
|
| |
$95
|
| |
$98
|
| |
$100
|
| |
$102
|
| |
$50
|
| |
$21
|
| |
$18
|
|
Selected Comparable Company
|
| |
EV/2025E Revenue
|
|
Catalyst Pharmaceuticals, Inc.
|
| |
2.5x
|
|
Collegium Pharmaceutical, Inc.
|
| |
2.2x
|
|
Heron Therapeutics, Inc.
|
| |
1.2x
|
|
Karyopharm Therapeutics Inc.
|
| |
0.4x
|
|
Morphosys AG
|
| |
1.7x
|
|
Pharming Group N.V.
|
| |
2.7x
|
|
Puma Biotechnology, Inc.
|
| |
0.7x
|
|
Rigel Pharmaceuticals, Inc.
|
| |
1.1x
|
|
Xeris Biopharma Holdings Inc.
|
| |
1.7x
|
|
Median | | |
1.7x
|
|
Acquiror / Target
|
| |
Announcement
Date |
| |
EV/2Y Fwd
Revenue |
|
Gurnet Point Capital and Novo Holdings A/S / Paratek Pharmaceuticals, Inc.
|
| | June 2023 | | |
1.8x
|
|
Chiesi Farmaceutici S.p.A / Amryt Pharma Plc
|
| | January 2023 | | |
3.0x
|
|
Alcon AG / Aerie Pharmaceuticals, Inc.
|
| | August 2022 | | |
4.3x
|
|
Innoviva, Inc. / La Jolla Pharmaceutical Company
|
| | July 2022 | | |
2.1x
|
|
Gurnet Point Capital and Patient Square Capital / Radius Health, Inc
|
| | June 2022 | | |
3.0x
|
|
Collegium Pharmaceutical, Inc. / BioDelivery Sciences International, Inc.
|
| | February 2022 | | |
2.1x
|
|
Supernus Pharmaceuticals, Inc. / Adamas Pharmaceuticals, Inc.
|
| | October 2021 | | |
3.3x
|
|
Pacira BioSciences, Inc. / Flexion Therapeutics, Inc.
|
| | October 2021 | | |
2.7x
|
|
Covis Group S.à r.l. / AMAG Pharmaceuticals, Inc.
|
| | October 2020 | | |
2.8x
|
|
Median | | | | | |
2.8x
|
|
Selected Company
|
| |
EV/2025E Revenue
Trading Multiple |
|
Catalyst Pharmaceuticals, Inc.
|
| |
2.5x
|
|
Collegium Pharmaceutical, Inc.
|
| |
2.2x
|
|
Heron Therapeutics, Inc.
|
| |
1.2x
|
|
Karyopharm Therapeutics Inc.
|
| |
0.4x
|
|
Morphosys AG
|
| |
1.7x
|
|
Pharming Group N.V.
|
| |
2.7x
|
|
Puma Biotechnology, Inc.
|
| |
0.7x
|
|
Rigel Pharmaceuticals, Inc.
|
| |
1.1x
|
|
Xeris Biopharma Holdings Inc.
|
| |
1.7x
|
|
Median | | |
1.7x
|
|
Date Announced
|
| |
Target
|
| |
Acquiror
|
| |
EV / 2-Year
Forward Revenue Multiple |
|
Jun-23
|
| | Paratek Pharmaceuticals, Inc. | | | Gurnet Point Capital and Novo Holdings A/S | | |
1.8x
|
|
Jan-23
|
| | Amryt Pharma Plc | | | Chiesi Farmaceutici S.p.A | | |
3.0x
|
|
Aug-22
|
| | Aerie Pharmaceuticals, Inc. | | | Alcon AG | | |
4.3x
|
|
Jul-22
|
| | La Jolla Pharmaceutical Company | | | Innoviva, Inc. | | |
2.1x
|
|
Jun-22
|
| | Radius Health, Inc. | | | Gurnet Point Capital and Patient Square Capital | | |
3.0x
|
|
Feb-22
|
| |
BioDelivery Sciences International, Inc.
|
| | Collegium Pharmaceutical, Inc. | | |
2.1x
|
|
Oct-21
|
| | Adamas Pharmaceuticals, Inc. | | | Supernus Pharmaceuticals, Inc. | | |
3.3x
|
|
Oct-21
|
| | Flexion Therapeutics, Inc. | | | Pacira BioSciences, Inc. | | |
2.7x
|
|
Oct-20
|
| | AMAG Pharmaceuticals, Inc. | | | Covis Group S.à r.l | | |
2.8x
|
|
Median | | | | | | | | |
2.8x
|
|
Name
|
| |
Cash ($)(1)
|
| |
Equity ($)(2)
|
| |
Perquisites/
Benefits($)(3) |
| |
Total ($)
|
| ||||||||||||
| | | | 4,809,690 | | | | | | 11,616,757 | | | | | | 78,722 | | | | | | 16,505,169 | | | |
Andrew Saik
|
| | | | 1,737,720 | | | | | | 1,631,680 | | | | | | 39,361 | | | | | | 3,408,761 | | |
Michelle Berrey
|
| | | | 2,872,400 | | | | | | 1,756,054 | | | | | | 24,960 | | | | | | 4,653,414 | | |
Linda Richardson
|
| | | | 1,542,920 | | | | | | 1,378,309 | | | | | | 11,871 | | | | | | 2,933,100 | | |
Jared Freedberg
|
| | | | 1,523,160 | | | | | | 1,392,445 | | | | | | 39,361 | | | | | | 2,954,966 | | |
|
Exhibit No.
|
| |
Description
|
|
|
(a)(1)(A)
|
| | Offer to Purchase, dated October 11, 2023 (incorporated by reference to Exhibit (a)(1)(i) to the Tender Offer Statement on the Schedule TO). | |
|
(a)(1)(B)
|
| | Form of Letter of Transmittal (incorporated by reference to Exhibit (a)(1)(ii) to the Tender Offer Statement on the Schedule TO). | |
|
(a)(1)(C)
|
| | Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(iii) to the Tender Offer Statement on the Schedule TO). | |
|
(a)(1)(D)
|
| | Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(iv) to the Tender Offer Statement on the Schedule TO). | |
|
(a)(1)(E)
|
| | Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(v) to the Tender Offer Statement on the Schedule TO). | |
|
(a)(1)(F)
|
| | Summary Advertisement, published on October 11, 2023, in The New York Times (incorporated by reference to Exhibit (a)(1)(vi) to the Tender Offer Statement on the Schedule TO). | |
|
(a)(5)(A)
|
| | Press Release of Intercept Pharmaceuticals, Inc., dated September 26, 2023 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed by Intercept Pharmaceuticals, Inc. on September 26, 2023). | |
|
(a)(5)(B)*
|
| | Opinion of Barclays Capital Inc., dated September 26, 2023 (included as Annex I to this Schedule 14D-9). | |
|
(a)(5)(C)*
|
| | Opinion of Centerview Partners LLC, dated September 26, 2023 (included as Annex II to this Schedule 14D-9). | |
|
(a)(5)(D)
|
| | Email to employees (incorporated by reference to Exhibit 99.1 to the Schedule 14D-9C filed by Intercept on September 26, 2023). | |
|
(a)(5)(E)
|
| | Transaction Social Media Guidelines Email (incorporated by reference to Exhibit 99.2 to the Schedule 14D-9C filed by Intercept on September 26, 2023). | |
|
(a)(5)(F)
|
| | Press Release of Intercept Pharmaceuticals, Inc., dated September 26, 2023 (incorporated by reference to Exhibit 99.3 to the Schedule 14D-9C filed by Intercept on September 26, 2023). | |
|
(a)(5)(G)
|
| | Message from David Ford About Benefits (incorporated by reference to Exhibit 99.1 to the Schedule 14D-9C filed by Intercept on September 28, 2023). | |
|
(a)(5)(H)
|
| | Email message from CEO Jerry Durso to All Intercept Employees Regarding All Employee Update with Alfasigma (incorporated by reference to Exhibit 99.1 to the Schedule 14D-9C filed by Intercept on September 28, 2023). | |
|
(a)(5)(I)
|
| | Email message from Alfasigma CEO Francesco Balestrieri to all Intercept employees (incorporated by reference to Exhibit 99.1 to the Schedule 14D-9C filed by Intercept on October 10, 2023). | |
|
(a)(5)(J)
|
| | Press Release issued by Alfasigma S.p.A., dated October 11, 2023 (incorporated by reference to Exhibit (a)(5)(iii) to the Tender Offer Statement on the Schedule TO). | |
|
(e)(1)
|
| | Agreement and Plan of Merger, dated September 26, 2023, among Intercept Pharmaceuticals, Inc., Alfasigma S.p.A. and Interstellar Acquisition Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Intercept on September 26, 2023). | |
|
(e)(2)
|
| | Confidentiality Agreement, dated July 10, 2023, between Intercept Pharmaceuticals, Inc. and Alfasigma S.p.A. (incorporated by reference to Exhibit (d)(2) to the Tender Offer Statement on the Schedule TO). | |
|
(e)(3)
|
| | Intercept Pharmaceuticals, Inc. Amended and Restated Equity Incentive Plan (incorporated by reference to Exhibit 10.11 to the Form 10-Q filed by Intercept on August 3, 2022). | |
|
Exhibit No.
|
| |
Description
|
|
|
(e)(4)
|
| | Intercept Pharmaceuticals, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 10-Q filed by Intercept on August 2, 2023). | |
|
(e)(5)
|
| | Form of Stock Option Grant Notice and Agreement for Directors (incorporated by reference to Exhibit 10.13 to the Form 10-Q filed by Intercept on August 3, 2022). | |
|
(e)(6)
|
| | Form of Stock Option Grant Notice and Agreement for Employees and Consultants (incorporated by reference to Exhibit 10.12 to the Form 10-Q filed by Intercept on August 3, 2022). | |
|
(e)(7)
|
| | Form of Restricted Stock Unit Award Grant Notice and Agreement for Directors (incorporated by reference to Exhibit 10.15 to the Form 10-Q filed by Intercept on August 3, 2022). | |
|
(e)(8)
|
| | Form of Restricted Stock Unit Award Grant Notice and Agreement for Employees and Consultants (incorporated by reference to Exhibit 10.14 to the Form 10-Q filed by Intercept on August 3, 2022). | |
|
(e)(9)
|
| | Form of Performance Stock Unit Grant Notice and Agreement (incorporated by reference to Exhibit 10.16 to the Form 10-Q filed by Intercept on August 3, 2022). | |
|
(e)(10)
|
| | 2022 Cash Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Intercept on January 31, 2022). | |
|
(e)(11)
|
| | 2022 Cash Incentive Plan — Form of Performance-Based Award Agreement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed by Intercept on January 31, 2022). | |
|
(e)(12)
|
| | 2023 Cash Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Intercept on February 2, 2023). | |
|
(e)(13)
|
| | 2023 Cash Incentive Plan — Form of Performance-Based Award Agreement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed by Intercept on February 2, 2023). | |
|
(e)(14)
|
| | Employment Agreement, effective April 14, 2017, between Intercept Pharmaceuticals, Inc. and David Ford (incorporated by reference to Exhibit 10.1 to the Form 10-Q filed by Intercept on August 3, 2017). | |
|
(e)(15)
|
| | Amended and Restated Employment Agreement, dated as of December 9, 2020, between Intercept Pharmaceuticals, Inc. and Jerome Durso (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Intercept on December 10, 2020). | |
|
(e)(16)
|
| | Employment Agreement, effective as of December 18, 2020, between Intercept Pharmaceuticals, Inc. and Jared Freedberg (incorporated by reference to Exhibit 10.21 to the Form 10-K filed by Intercept on February 25, 2021). | |
|
(e)(17)
|
| | Employment Agreement, effective February 15, 2021, between Intercept Pharmaceuticals, Inc. and Linda Richardson (incorporated by reference to Exhibit 10.3 to the Form 10-Q filed by Intercept on May 6, 2021). | |
|
(e)(18)
|
| | Employment Agreement, effective May 17, 2021, between Intercept Pharmaceuticals, Inc. and Andrew Saik (incorporated by reference to Exhibit 10.1 to the Form 10-Q filed by Intercept on July 29, 2021). | |
|
(e)(19)
|
| | Employment Agreement, effective June 2, 2021, between Intercept Pharmaceuticals, Inc. and M. Michelle Berrey (incorporated by reference to Exhibit 10.2 to the Form 10-Q filed by Intercept on July 29, 2021). | |
|
(e)(20)
|
| | Employment Agreement, effective April 21, 2022, between Intercept Pharmaceuticals, Inc. and Rocco Venezia (incorporated by reference to Exhibit 10.4 to the Form 10-Q filed by Intercept on May 6, 2022). | |
|
(e)(21)
|
| | Form of Indemnification Agreement for directors and executive officers of Intercept Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.7 to the Form S-1 filed by Intercept on September 4, 2012, Registration No. 333-183706). | |
|
|
| |
Execution Version
|
|
This ‘SC 14D9’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/31/31 | ||||
12/31/28 | ||||
1/26/24 | ||||
12/31/23 | ||||
11/7/23 | ||||
10/25/23 | ||||
Filed on: | 10/11/23 | SC TO-T | ||
10/10/23 | SC 13G/A, SC TO-C, SC14D9C | |||
10/3/23 | ||||
10/1/23 | ||||
9/30/23 | ||||
9/28/23 | SC14D9C | |||
9/26/23 | 8-K, SC TO-C, SC14D9C | |||
9/25/23 | 4 | |||
9/24/23 | ||||
9/22/23 | ||||
9/19/23 | ||||
9/18/23 | 4 | |||
9/17/23 | ||||
9/16/23 | ||||
9/15/23 | ||||
9/12/23 | ||||
9/11/23 | ||||
9/10/23 | ||||
9/7/23 | ||||
9/5/23 | ||||
9/1/23 | ||||
8/29/23 | ||||
8/28/23 | ||||
8/23/23 | ||||
8/21/23 | ||||
8/19/23 | ||||
8/15/23 | ||||
8/14/23 | ||||
8/10/23 | ||||
8/9/23 | ||||
8/4/23 | ||||
8/2/23 | 10-Q, 8-K | |||
8/1/23 | 4 | |||
7/31/23 | ||||
7/28/23 | ||||
7/27/23 | ||||
7/25/23 | ||||
7/10/23 | SC 13G/A | |||
6/30/23 | 10-Q | |||
6/26/23 | ||||
6/23/23 | 4, 8-K | |||
6/22/23 | 8-K | |||
6/15/23 | ||||
6/5/23 | ||||
5/31/23 | ||||
5/26/23 | ||||
5/22/23 | 8-K | |||
5/19/23 | 8-K | |||
5/4/23 | ||||
5/2/23 | ||||
4/26/23 | ||||
3/31/23 | 10-Q | |||
3/2/23 | 10-K, 8-K | |||
2/2/23 | 8-K, SC 13G/A | |||
12/31/22 | 10-K, 4, ARS | |||
11/8/22 | ||||
9/26/22 | ||||
9/25/22 | ||||
8/3/22 | 10-Q, 4, 8-K | |||
5/6/22 | 10-Q, 8-K | |||
4/21/22 | ||||
1/31/22 | 4, 8-K | |||
12/31/21 | 10-K, 4 | |||
7/29/21 | 10-Q, 8-K | |||
6/2/21 | 4 | |||
5/17/21 | 4 | |||
5/6/21 | 10-Q, 8-K | |||
2/25/21 | 10-K, 4, 8-K | |||
2/15/21 | 3, 4 | |||
12/31/20 | 10-K, 4 | |||
12/18/20 | ||||
12/10/20 | 8-K | |||
12/9/20 | 8-K | |||
8/3/17 | 10-Q | |||
4/14/17 | ||||
9/4/12 | CORRESP, D/A, S-1 | |||
List all Filings |